pioglitazone + insulin

Pioglitazone + insulin is a combination therapy used to treat type 2 diabetes mellitus in adults who have insufficient glycemic control with either agent alone, particularly when metformin is inappropriate due to contraindications or intolerance. Pioglitazone is a thiazolidinedione that acts as an agonist of peroxisome proliferator-activated receptor gamma (PPARγ), improving tissue sensitivity to endogenous or exogenous insulin and reducing hepatic gluconeogenesis. Insulin, a peptide hormone, directly lowers blood glucose by promoting cellular uptake of glucose and inhibiting hepatic glucose production. The combination enhances glycemic control but increases the risk of fluid retention, weight gain, heart failure, and hypoglycemia compared to monotherapy. This regimen is primarily indicated for type 2 diabetes management[1][5][6].

Brand names

Actos + insulinGlustin + insulinGlizone + insulinPioz + insulinZactos + insulin

Other names

pioglitazone and insulin combination therapy